1. Home
  2. LSAK vs PSTX Comparison

LSAK vs PSTX Comparison

Compare LSAK & PSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSAK
  • PSTX
  • Stock Information
  • Founded
  • LSAK 1997
  • PSTX 2014
  • Country
  • LSAK South Africa
  • PSTX United States
  • Employees
  • LSAK N/A
  • PSTX N/A
  • Industry
  • LSAK Investment Bankers/Brokers/Service
  • PSTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LSAK Finance
  • PSTX Health Care
  • Exchange
  • LSAK Nasdaq
  • PSTX Nasdaq
  • Market Cap
  • LSAK N/A
  • PSTX 285.1M
  • IPO Year
  • LSAK N/A
  • PSTX 2020
  • Fundamental
  • Price
  • LSAK $4.92
  • PSTX $3.32
  • Analyst Decision
  • LSAK
  • PSTX Strong Buy
  • Analyst Count
  • LSAK 0
  • PSTX 3
  • Target Price
  • LSAK N/A
  • PSTX $14.67
  • AVG Volume (30 Days)
  • LSAK 22.6K
  • PSTX 467.2K
  • Earning Date
  • LSAK 09-10-2024
  • PSTX 08-06-2024
  • Dividend Yield
  • LSAK N/A
  • PSTX N/A
  • EPS Growth
  • LSAK N/A
  • PSTX N/A
  • EPS
  • LSAK N/A
  • PSTX N/A
  • Revenue
  • LSAK $551,325,000.00
  • PSTX $82,502,000.00
  • Revenue This Year
  • LSAK $9.63
  • PSTX $17.26
  • Revenue Next Year
  • LSAK $8.35
  • PSTX N/A
  • P/E Ratio
  • LSAK N/A
  • PSTX N/A
  • Revenue Growth
  • LSAK 6.72
  • PSTX N/A
  • 52 Week Low
  • LSAK $3.00
  • PSTX $1.60
  • 52 Week High
  • LSAK $5.33
  • PSTX $4.27
  • Technical
  • Relative Strength Index (RSI)
  • LSAK 57.40
  • PSTX 56.29
  • Support Level
  • LSAK $4.71
  • PSTX $3.01
  • Resistance Level
  • LSAK $5.00
  • PSTX $3.55
  • Average True Range (ATR)
  • LSAK 0.15
  • PSTX 0.19
  • MACD
  • LSAK 0.01
  • PSTX 0.00
  • Stochastic Oscillator
  • LSAK 77.78
  • PSTX 49.36

About PSTX Poseida Therapeutics Inc.

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Share on Social Networks: